An Investor Shows Interest in Kali Inc (OTCMKTS:KALY) ‘s Cannabis Extract Biopharmaceutical Technology: Kali Confirms Acquisition Interest

Kali Inc (OTCMKTS:KALY) doing business as kali Extracts has confirmed an investor’s acquisition interest in its Cannabis Extract Biopharmaceutical Technology. Chief Executive Officer of Kali, Frederick Ferri, said interest in its Cannabis Extract Biopharmaceutical Technology from an investor shows that its technology is undervalued. The company would release an update on acquisition interest on October 30, 2019.

Kali takes over NCMB in Q4 2018

Kali has taken over NCMB, which operates the patented cannabis extraction process in Q4 2018. Before acquired by Kali, NCMB is a leading player in developing plant-derived cannabinoid therapeutics with the help of the patented development process in its four years of operation. The manufacturing expertise, the established regulatory framework, and an intellectual property portfolio are the result of NCMB’s four-year operation.

Market for COPD

The market for chronic obstructive pulmonary disease (COPD) would touch $14 billion by the year 2025. Demand for Type 2 diabetes treatment is expected to reach $64 billion by the year 2026. The market for overall pain management is forecasted to reach $83 billion by the year 2024. Kali would supply CBD products for the treatment of these diseases.

Kali has filed a patent for a new formulation for the treatment of COPD symptoms. The company also applied for the trademark ‘RespRx,’ a brand name for the CBD formulation to treat COPD symptoms and other respiratory conditions. Kali is at an advantage with its new formulations for COPD cure.

To comply with US FDA requirements, Kali is in the process of getting its proprietary extracts, which are derived from the US-patented extraction process, certified. Kali has established substantial achievements since the update of the biopharmaceuticals strategy. The company associated with a major university to test and evaluate COPD treatment formulations. It will soon kickoff this evaluation process and issues an update at a later date. Advances made in the treatments helped Kali to establish new partnerships. The company would issue an update on new partnerships.

Puration Inc has obtained a limited license for the patented process of Kali to infuse cannabis extracts in its beverages. Kali is also marketing CBD infused candies under its brand name – Hemp4mula.


Kali Inc (OTCMKTS:KALY) Posts The $0.05 Revenue Growth On Its Website

Kali Inc (OTCMKTS:KALY) considers researcher Goldman Small Cap one of the most reliable analysts. The group unveiled the report from its analysts that focused on the deals of the company. From the report, it is easy to tell that the biopharmaceutical cannabis extract business of KALY has been an impressive one in terms of positive progress. The report by the body has also been updated on the company’s website and thus anyone wanting to get the updates can visit the relevant website. The report from a speculative point of view projects the company’s price per share as standing at about $0.05.

The company’s progress

Market observers following on the company’s progress have also shared their thoughts. They say that the generation of these high revenues and operating profits are a sure sign that the company is headed towards greatness. KALY’s organization has been a good one considering the way it has been setting up its pharmaceutical development milestones. Its near-term revenue projections are also reasonable, according to analysts. With all this working for the business guru, it shouldn’t catch one by surprise that the shares will soon be playing at the $0.05 figure.

The company’s CEO sometime back gave updates regarding the company and its objectives. An official speaking from the point of anonymity says the update may have trigged the analyst’s report. The CEO had spoken rather elaborately regarding their cannabis extract biopharmaceutical business. They sought to get $170 billion in line with their pharmaceutical treatments.

Other achievements

The CEO also spoke regarding the company’s new patent and trademark applications. That was in line with the CBD Formulation to be applied in the handling of Chronic Obstructive Pulmonary Disease (COPD). The company remains dedicated to continuity in line with the development of such helpful CBD formulations.

The report is rather elaborate, considering it even covers several of the company’s CBD extraction contracts. The hemp farming operations have been ongoing, and reports indicate the company may already have spent about $15 million.

The company’s 2019YTD financials were impressive with a figure of 250% recorded in terms of revenue growth.

This report has also disclosed details regarding the business collaboration between the company and Puration Inc (OTCMKTS:PURA).


Kali Inc (OTCMKTS:KALY) Strikes CBD Beer And CBD Coffee Partnership With Puration Inc (OTCMKTS:PURA)

Kali Inc (OTCMKTS:KALY) announced on Tuesday that it struck a partnership agreement with Puration Inc (OTCMKTS:PURA) through which they will collaborate to create CBD-infused beer and coffee.

The recently announced partnership fulfills a Puration’s announcement about a week ago through which it revealed that it would collaborate with a beer producer to make CBD-infused beer. Puration also announced that it will team up with a coffee producer to make CBD-infused coffee.  The partnership between Kali and Pura will focus on a specific extract that will be infused into coffee.

Kali has been making significant progress with its CBD-infused beverages

Kali owns a cannabis extraction patent in the U.S, which means that e partnership is advantageous for Puration with their plan to produce CBD-infused beverages with 10 mg 25 mg CBD. So far Puration has produced more than 1 million CBD-infused beverages that were sold in the U.S market in 2018. The company’s sales target for 2019 is 4 million.

Puration and Kali will release a presentation in the coming week so that they can reveal more details about their joint endeavor involving beer and coffee. The partnership also highlights the level of innovation that some cannabis companies are pursuing to tap deeper into the rapidly growing market. This also means that the cannabis industry is benefiting from a wider variety of products.

Kali is a biopharma that invests its resources in the discovery, development, and sale of innovative treatments, especially those made from cannabis extracts. Its therapeutics target a wide range of health conditions.

Kali has been on a mission to expand its operations

Kali has also been expanding its business so that it can increase its production capacity and market share. It even acquired another cannabis firm called NCM Biotech towards the end of 2028. NCM Biotech was a strategic acquisition for Kali because the firm was one of the key players in the creation of cannabis-based therapeutics.  The acquisition also provided Kali with access to a strong portfolio of intellectual property as well as manufacturing and regulatory expertise which were added advantages.


Mondelez International Inc (NASDAQ:MDLZ) Includes CBD Of Kali Inc (OTCMKTS:KALY) And Puration Inc (OTCMKTS:PURA) In New Snacks

Kali Inc (OTCMKTS:KALY) and Puration Inc (OTCMKTS:PURA) issued an update to the shareholders that Mondelez International Inc (NASDAQ:MDLZ) plans to include CBD in its snacks. Dirk Van de Put, Chief Executive Officer of Mondelez said the company is considering using CBD in its new products but within the ambit of a legal framework.

Mondelez will not include CBD in its family brands like Oreos. However, the company plans to use CBD in other products. It may even launch a new product line for the cannabidiol. According to CEO of Mondelez, the launch of CBD infused products will take some time to enter the mainstream food market. He said the company is exploring the claimed benefits of cannabidiol.

The product line of Mondelez comprise Milka, Chiclets, Ritz, Oreo, Toblerone, Marabou, Cadbury, Halls, Dentyne, Freia, TUC, Cote d’Or, and Tang powered beverages.

The managements of Kali and PURA have seen the consideration to include CBD in the products of Mondelez as a validation of their business progress and strategies. They expect new investments for business expansion on the backdrop of Mondelez news. It also bodes well for the increased demand of CBD infused products.

PURA holds the license of patented Cannabis Extraction Process, which is owned by Kali, in the US. The company has got expertise in the production and refining of EVERx CBD Sports Water, a CBD infused sports water.

PURA and Kali have jointly worked to refine the EVERx CBD sports water and introduce in the sports nutrition market as a leading Cannabidiol infused beverage. They are also working to launch innovative CBD infused beverages. PURA has generated sales of over $1 million in the year 2018.

CBD infused confections

Kali has unveiled its own cannabidiol infused confections under the trademark Hemp4mula. The first product under this brand is the Hemp4mula gum. Both PURA and Kali have made available their own Hemp4mula gum for purchase online.

Health Benefits

CBD is derived from hemp and marijuana plants. It is non-psychoactive. CBD will not cause any high associated with cannabis. The health benefits of CBD include ability to manage anxiety and reduce pain.

Pin It on Pinterest